Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 38,100 shares, a drop of 54.5% from the March 31st total of 83,800 shares. Based on an average trading volume of 469,300 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are sold short.

Bioxytran Price Performance

Shares of OTCMKTS:BIXT opened at $0.16 on Wednesday. Bioxytran has a 1 year low of $0.06 and a 1 year high of $0.23. The stock’s fifty day moving average price is $0.15 and its 200-day moving average price is $0.11. The company has a market cap of $15.62 million, a P/E ratio of -15.59 and a beta of 0.98.

Bioxytran (OTCMKTS:BIXT) last released its quarterly earnings data on Thursday, April 3rd. The company reported ($0.01) earnings per share for the quarter.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.